Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Chaudhury, Sonali  [Clear All Filters]
2024
Verma A, Chi Y-Y, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li H-T, Liang G, Leong R, Brown PA, et al. Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers (Basel). 2024;16(3).
Abraham RS, Basu A, Heimall JR, Dunn E, Yip A, Kapadia M, Kapoor N, Satter LForbes, Buckley R, O'Reilly R, et al. Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia. Clin Immunol. 2024:109942.
2023
Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, Krumbholz M, Luesink M, Naumann-Bartsch N, et al. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia. 2023.
2022
Carpenter PA, Kang HJin, Yoo KHee, Zecca M, Cho B, Lucchini G, Nemecek ER, Schultz KR, Stepensky P, Chaudhury S, et al. Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1/2 iMAGINE study. Transplant Cell Ther. 2022.
Krishnamurti L, Arnold SD, Haight A, Abraham A, Guilcher GMt, John T, Bakshi N, Shenoy S, Syrjala K, Martin PL, et al. Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle . JMIR Res Protoc. 2022;11(7):e36780.
Chaudhury S, Schultz KR. When should a Reduced intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HSCT) be Considered in Pediatric CML-CP1?. Transplant Cell Ther. 2022;28(7):347-348.
2021
Shah NC, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier GDE, Godder K, Grimley M, et al. Granulocyte Colony-Stimulating Factor is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplant Cell Ther. 2021.
Rossoff J, Jacobsohn D, Kwon S, Kletzel M, Duerst RE, Tse WT, Schneiderman J, Chaudhury S. Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatr Blood Cancer. 2021:e29087.
2020
Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, et al. A Phase 3, Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who Failed to Respond to Steroid Treatment for Acute GVHD. Biol Blood Marrow Transplant. 2020.
2018
Bhatt ST, Bednarski JJ, Berg J, Trinkaus K, Murray L, Hayashi R, Schulz G, Hente M, Grimley M, Chan KWah, et al. Immune Reconstitution and Infection Patterns Following Early Alemtuzumab and Reduced Intensity Transplantation for Non-Malignant Disorders in Pediatric Patients. Biol Blood Marrow Transplant. 2018.
Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME. Practice Patterns of Physician Treatment for Pediatric Chronic Myeloid Leukemia (CML). Biol Blood Marrow Transplant. 2018.
2016
Madden LM, Hayashi RJ, Chan KWah, Pulsipher MA, Douglas D, Hale GA, Chaudhury S, Haut P, Kasow KA, Gilman A, et al. Long-term Follow-up after Reduced Intensity Conditioning and Stem Cell Transplantation for Childhood Non-Malignant Disorders. Biol Blood Marrow Transplant. 2016.